Atara gets FDA priority review for Tabelecleucel application
Source: SeekingAlpha
2025-07-24 10:49:03 ET
More on Atara Biotherapeutics
- Atara gains after insider purchase
- Atara Biotherapeutics prices $16M public offering
- Seeking Alpha’s Quant Rating on Atara Biotherapeutics
- Historical earnings data for Atara Biotherapeutics
- Financial information for Atara Biotherapeutics
Read the full article on Seeking Alpha
For further details see:
Atara gets FDA priority review for Tabelecleucel application
Atara Biotherapeutics Inc.
NASDAQ: ATRA
ATRA Trading
-4.57% G/L:
$6.05 Last:
176,860 Volume:
$6.18 Open:
ATRA Latest News
ATRA Stock Data
$36,411,687
4,838,068
18.37%
20
N/A
Biotechnology & Life Sciences
Healthcare
US
Thousand Oaks
